Navigation Links
Poniard Pharmaceuticals Announces Progression-Free Survival Data From Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
Date:5/28/2009

nths for those who received modified FOLFOX-6, containing oxaliplatin.
  • Of the 51 patients in the FOLPI treatment arm, 75 percent achieved disease control (defined as complete response, partial response or stable disease); two patients with a complete response, nine patients with a partial response and 27 patients with stable disease. In the FOLFOX treatment arm of 50 patients, 76 percent achieved disease control; three patients with a complete response, 11 patients with a partial response and 24 patients with stable disease.
  • Only 29 percent of the patients who received FOLPI showed evidence of neurotoxicity compared with 60 percent of patients treated with FOLFOX. In addition, 16 percent of FOLFOX-treated patients exhibited severe (Grade 3/4) neurotoxicity, whereas no FOLPI-treated patients showed evidence of severe neurotoxicity. Three different measurements of neuropathy were statistically significant for FOLPI as a potential neuropathy-sparing alternative to FOLFOX (p<0.0019).
  • With regard to hematologic toxicities, thrombocytopenia and neutropenia were more frequent and severe with the FOLPI regimen compared with FOLFOX. However, only one episode of febrile neutropenia and no bleeding complications have been observed to date. In addition, 83 percent of the planned picoplatin dose of 150 mg/meter squared was able to be delivered monthly in the 51 patients treated in the FOLPI treatment arm of the trial.
  • Nonhematologic adverse events, including gastrointestinal toxicity, were similar between the treatment groups, with the exception of alopecia, which occurred more frequently with FOLPI.

  • "We continue to be encouraged by these interim, proof-of-concept Phase 2 safety and efficacy results, which suggest the potential of picoplatin in FOLPI as a neuropathy-sparing therapeutic alternative to the use of FOLFOX for the first-line treatment of metast
    '/>"/>

    SOURCE Poniard Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
    2. Poniard Pharmaceuticals to Present New Data from Phase 2 Clinical Trials of Picoplatin in Multiple Tumor Types at the 45th Annual Meeting of the American Society of Clinical Oncology
    3. Poniard Completes Patient Enrollment Target in Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
    4. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
    5. Poniard Pharmaceuticals Announces Management Changes and Focus on Development and Commercialization of Picoplatin
    6. Poniard Pharmaceuticals Announces Final Top-Line Results from Phase 1 Trial Demonstrating Positive Bioavailability with Oral Picoplatin
    7. Poniard Announces Positive Efficacy and Safety Data From Phase 1 Trial of Picoplatin in Multiple Tumor Types Including Ovarian Cancer
    8. Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer
    9. Poniard Announces Positive First-Line Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in Patients with Metastatic Hormone Refractory Prostate Cancer
    10. Poniard to Present Clinical Data From Picoplatin Trials in Multiple Tumor Types at American Society of Clinical Oncology 2008 Annual Meeting
    11. Poniard Pharmaceuticals Licenses Kinase Inhibitors From The Scripps Research Institute
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/6/2015)... , July 6, 2015  Student-athletes at community ... benefit from a recently established partnership between ImPACT ... California . The partnership enables member institutions ... distribute ImPACT ® concussion baseline and post-injury ... majority of community colleges in California ...
    (Date:7/6/2015)... , July 6, 2015  EndoChoice Holdings, Inc. ... second quarter 2015 financial results on Thursday, August 6, ... will hold a conference call on Thursday, August 6, ... The dial-in numbers are (866) 807-9684 for domestic callers ... of the conference call will be available on the ...
    (Date:7/6/2015)... 2015  Nitin Tandon, M.D., UTHealth neurosurgeon and ... Hermann Mischer Neuroscience Institute at the Texas ... technology into the skull of a 36-year-old epilepsy ... – the first time this procedure has been ... is a neurological condition that affects nearly three ...
    Breaking Medicine Technology:California Community College Athletic Departments to Benefit from ImPACT Concussion Baseline Testing Offered by Student Insurance 2California Community College Athletic Departments to Benefit from ImPACT Concussion Baseline Testing Offered by Student Insurance 3EndoChoice to Report Second Quarter 2015 Financial Results on August 6, 2015 2Memorial Hermann Successfully Completes System's First NeuroPace RNS System Procedure for Epilepsy Patient 2Memorial Hermann Successfully Completes System's First NeuroPace RNS System Procedure for Epilepsy Patient 3Memorial Hermann Successfully Completes System's First NeuroPace RNS System Procedure for Epilepsy Patient 4
    ... Calif., Dec. 17 PEAK Surgical, Inc., a ... dissection system based on a,proprietary technology, announced today ... granted the company 510(k) clearance to market its,PEAK(R) ... tissue during,plastic and reconstructive, ENT (ear, nose and ...
    ... Calif., Dec. 17 Neurobiological,Technologies, Inc. (NTI(R)) (Nasdaq: ... independent,Data Safety Monitoring Board (DSMB) has determined that ... of acute ischemic stroke are unlikely,to show benefit. ... enrollment in,the trials. NTI will obtain and analyze ...
    Cached Medicine Technology:PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 2PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 3PEAK Surgical Receives 510(k) Clearance to Market PEAK(R) Surgery System for Use in Expanded Indications 4Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis 2
    (Date:7/6/2015)... ... July 06, 2015 , ... ... eliminates 100% of all acids, chemicals and impurities; it also properly mineralizes the ... because it contains harmful contaminants.  These harmful contaminants are a byproduct of how ...
    (Date:7/6/2015)... ... ... University of Pittsburgh Cancer Institute (UPCI) scientists recently led a panel ... tests that better incorporate personalized medicine into diagnosing the condition. , Their clinical ... in the July issue of the scientific journal Thyroid . The American ...
    (Date:7/6/2015)... Los Angeles, CA (PRWEB) , ... July 06, 2015 , ... On June 22, 2015, Fox News in a report ... that by the time they turn age 35 a quarter of all women in the U.S. ... hair loss is stigmatized and rarely discussed. One woman, a former beauty queen, ...
    (Date:7/6/2015)... ... July 06, 2015 , ... ... Medical Spa industries, announces the return of its complimentary educational webinar series ... aesthetic medical business leaders creates success for their clients through targeted marketing, sales, ...
    (Date:7/6/2015)... Virginia Beach, Virginia (PRWEB) , ... July 06, ... ... United States choose fat-reduction procedures each year for aesthetic reasons, which is why ... the country. For a particular demographic, however, fat reduction has become more than ...
    Breaking Medicine News(10 mins):Health News:Pristine Water Filters.com Offers The 1st Water Revival System That Re-Mineralizes Drinking Water and Eliminates All Impurities and Chemicals 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:The Stigma of Female Hair Loss and Hair Restoration Solutions 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 2Health News:Acara Partners Announces Complimentary Educational Webinar Series for Cosmetic Medical Practices and MedSpas 3Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 2Health News:Learn How CoolSculpting® and Liposuction in Virginia Beach Help Military Members Stay the Course 3
    ... New Manager,s amendment holds tax burdens that will raise ... Dec. 20 Yesterday, Senator Reid released his Manager,s ... in the U.S. Senate. One provision in the amendment involved ... the health insurance industry. As the Congressional Budget Office has ...
    ... ... LLC recently named two QHR management clients to its “Top 100 ... Madison, Iowa), a QHR management client since 1982, and Monroe County ... by the company, which specializes in providing hospitals and other healthcare-related ...
    ... ... retested nearly 3,000 breast cancer specimens from the Province of Quebec following an inquiry ... some patients. , ... (PRWEB) December 20, 2009 -- Seattle-based PhenoPath Laboratories served as the reference laboratory for ...
    ... Federal government must not expand its role enabling abortions ... until problems remedied , Protection of life, conscience ... WASHINGTON, Dec. 19 The Senate health reform bill should ... of Galveston-Houston, Bishop William Murphy of Rockville Centre, New York, ...
    ... , WASHINGTON, Dec. 19 Official statement of Americans ... Leader Reid,s amendment to the Senate health care bill absolutely fails ... law and policy. It does not prevent federal funding of ... care providers who choose to exercise their rights of conscience, and ...
    ... , , Additional $15 ... WASHINGTON, Dec. 19 Today, the United States Congress approved an ... of the fiscal year 2010 Department of Defense (DOD) Appropriations package. ... appropriated to date for the new program since it was launched ...
    Cached Medicine News:Health News:Anthem Blue Cross and Blue Shield In Missouri Urges Missouri Senators Claire McCaskill and Christopher S. Bond to Not Support the Current Senate Health Care Reform Legislation 2Health News:Anthem Blue Cross and Blue Shield In Missouri Urges Missouri Senators Claire McCaskill and Christopher S. Bond to Not Support the Current Senate Health Care Reform Legislation 3Health News:QHR Hospital Clients Fort Madison Community Hospital, Monroe County Hospital Named to &#8220;Best in Value&#8221; Top 100 List 2Health News:Seattle-based PhenoPath Laboratories Retests Nearly 3,000 Breast Cancer Specimens from Quebec Breast Cancer Inquiry 2Health News:Seattle-based PhenoPath Laboratories Retests Nearly 3,000 Breast Cancer Specimens from Quebec Breast Cancer Inquiry 3Health News:Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops 2Health News:Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops 3Health News:Health Reform Bill Needs More Work Despite New Language on Abortion, Say Catholic Bishops 4Health News:Americans United for Life Action: 'Senate Health Care Bill Absolutely Fails To Meet Abortion and Life Protections.' 2Health News:Americans United for Life Action: 'Senate Health Care Bill Absolutely Fails To Meet Abortion and Life Protections.' 3Health News:Lung Cancer Alliance Hails New Federal Funding for Lung Cancer Research 2Health News:Lung Cancer Alliance Hails New Federal Funding for Lung Cancer Research 3
    ... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
    ... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    ... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
    Medicine Products: